Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13 nov. 2024 06h30 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024.
Liquidia to Present at the Stifel 2024 Healthcare Conference
12 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
06 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (LQDA) to report its third quarter 2024 financial results on November 13, 2024, via webcast at 8:30 a.m. ET
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
04 nov. 2024 08h00 HE
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA), to report its third quarter 2024 financial results via webcast at 8:30 a.m. ET on Friday, November 8, 2024.
Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm
30 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Liquidia Corporation...
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
30 sept. 2024 08h00 HE
|
Liquidia Corporation
Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm
16 sept. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSE:...
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
16 sept. 2024 09h41 HE
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
27 août 2024 22h00 HE
|
Bragar Eagel & Squire
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation...
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
22 août 2024 06h00 HE
|
Liquidia Corporation
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.